Bayer to present new data across oncology portfolio

Bayer (BAYRY) announced that new data from studies across their oncology portfolio will be presented at the upcoming 2026 American Society of Clinical Oncology, ASCO, Annual Meeting, taking place in Chicago from May 29-June 2. In total, 16 abstracts will be presented spanning multiple cancer types, including prostate cancers, breast cancer, lung cancers, salivary gland cancer, renal cell carcinoma and colorectal cancers, further supporting Bayer’s commitment to the research of treatments for cancers and encouraging scientific exchange. Primary results from the Phase II Aracog head-to-head trial evaluating Nubeqa versus enzalutamide in men with metastatic and non-metastatic castration-resistant prostate cancer or metastatic hormone-sensitive prostate cancer will be presented as an oral abstract and are additionally featured in the ASCO 2026 Annual Meeting Press Program. Data from a subgroup post-hoc analysis of the investigational Phase III Aranote trial investigating prostate-specific antigen outcomes of Nubeqa plus androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer will also be presented.